Search
Displaying 551–560 of 691 for “retinal diseases”
-
Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
Research NewsThe therapy delivers copies of the RORA gene to address multiple disease pathways.
-
Want to support this historic event? Sponsorship and exhibitor opportunities are available for organizations, foundations, and industry partners dedicated to advancing retinal research and innovation. Learn more by sending an email to Partnerships@FightingBlindness.org.
-
Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD
Eye on the CureDr. Lenore von Krusenstiern talks about Bluerock’s clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy.
-
Research News
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
-
Mental Health Advisory Council
The Foundation Fighting Blindness mental health initiative is guided by a mental health advisory council (MHAC) which includes five expert therapists (four of whom are blind or have low vision), a retinal specialist who has treated patients facing severe depression and anxiety, and a Foundation Board Member affected by vision loss who organized a local mental health support group.
-
Eye on the Cure Podcast | Episode 78: Dr. Sheldon Rowan
Eye on the CureDr. Rowan talks about the impact of the glycemic index, microbiome, and diet on the development of age-related macular degeneration and optimization of overall retinal health.
-
Share Your Vision: Heather Edwards
Beacon StoriesHeather Edwards has turned her personal journey with cone-rod dystrophy into a mission to support others facing similar challenges. Despite facing difficulties during her youth, Heather now uses her experiences to advocate for awareness and support for blinding diseases, emphasizing that blindness is a spectrum and each person’s experience is uniquely valuable.
-
Research News
The Phase 3 trial is expected to begin in Q1 2025
-
AREDS Formula Reduces Risk of Visual Acuity Loss for People with Geographic Atrophy
Research NewsPreviously, the formula was thought to only reduce risk of early age-related macular degeneration advancing to late-stage disease
-
Eye on the Cure Podcast | Episode 69: Dr. Francois Paquet-Durand
Eye on the CureFrancois Paquet-Durand, PhD, a professor from the University of Tübingen and co-founder of the company Mireca, talks to host Ben Shaberman about the long journey of an emerging, Foundation-funded drug for the treatment of certain forms of retinitis pigmentosa. The episode highlights the challenges that scientists often encounter when developing a drug for a retinal disease, and the persistence and tenacity that are required to keep it moving forward.
.png)
.png)
